Pharmatech comprises systems for the automated use and coordination of clinical information, medical devices, care paths, and pharmacologic agents into specific prescription and care-delivery processes tailored to meet individual patient needs. In ESRD, future suites of applications to run on hemodialysis, peritoneal dialysis machines, external computers and devices both in-center and in the home setting offer the potential to further automate billing and inventory, improve documentation, reduce medical errors, and decrease costs. On a clinical basis, these systems will aid nurses, physician assistants, nurse practitioners, and physicians in performing and overseeing a wide range of clinical activities that constitute 21st-century medicine. Future innovations may allow Pharmatech systems to learn by achieving defined outcomes. These developments offer the potential to provide customized ESRD care by integrating standard practices with individual patient characteristics and patient-specific needs. The development of Pharmatech represents one of the next advances in healthcare technology and will become an important component in the delivery of 21st-century medicine. Adoption of information technology (IT) has been prioritized by the federal government, and is a key component of US healthcare policy. The United States Agency for Healthcare Research and Quality is currently funding the development and implementation of a wide array of health IT applications. This extensive funding combined with rapid technologic advances will continue to drive Pharmatech development and the widespread implementation of medical IT in the coming decade.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/j.1525-139X.2011.00974.x | DOI Listing |
Eur J Breast Health
January 2025
Department of Biomedical Engineering, Faculty of Engineering, İzmir University of Economics, İzmir, Turkey.
Objective: The prevalence of breast cancer and gynaecological cancers is high, and these cancer types can occur consecutively as secondary cancers. The aim of our study is to determine the genes commonly expressed in these cancers and to identify the common hub genes and drug components.
Materials And Methods: Gene intensity values of breast cancer, gynaecological cancers such as cervical, ovarian and endometrial cancers were used from the Gene Expression Omnibus database Affymetrix Human Genome U133 Plus 2.
Clin Trials
January 2025
Department of Biostatistics, University of Washington, Seattle, WA, USA.
Background: N-of-1 trials compare two or more treatment options for a single participant. These trials have been used to study options for chronic conditions such as arthritis and attention deficit hyperactivity disorder. In addition, they have been suggested as a means to study interventions in rare populations that may not be tractable to include in standard clinical trials, such as treatment options for HIV-positive patients in need of organ transplant.
View Article and Find Full Text PDFChronobiol Int
January 2025
Department of Nutrition and Dietetics, Firat University, Elazig, Turkey.
The effects of chronotype and diet on obese individuals have been reported in previous studies. This study aimed to examine the relationship between the Mediterranean-DASH intervention for neurodegenerative delay (MIND) diet, chronotype and lifestyle factors in different types of overweight and obese people. 1100 obese individuals participated in this cross-sectional study.
View Article and Find Full Text PDFOrthod Craniofac Res
January 2025
UFR Odontologie, Université Paris Cité, Paris, France.
Objective: To assess the accuracy of three commercially available and one open-source deep learning (DL) solutions for automatic tooth segmentation in cone beam computed tomography (CBCT) images of patients with multiple dental impactions.
Materials And Methods: Twenty patients (20 CBCT scans) were selected from a retrospective cohort of individuals with multiple dental impactions. For each CBCT scan, one reference segmentation and four DL segmentations of the maxillary and mandibular teeth were obtained.
Muscle Nerve
January 2025
Department of Neurology, University at Buffalo Jacobs School of Medicine and Biomedical Sciences, New York, USA.
Introduction/aims: Neonatal Fc receptor (FcRn) inhibitors represent a promising treatment option for patients with generalized myasthenia gravis (gMG); however, data on clinical use are limited. The aim of this report is to describe one center's approach to efgartigimod dosing in patients with gMG.
Methods: Medical records of patients with acetylcholine receptor antibody-positive (AChR-Ab+) gMG whose symptoms were not adequately controlled by oral medications and/or intravenous immunoglobulin who received efgartigimod between January 2022 and January 2024 were retrospectively evaluated.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!